Myeloid-derived suppressor cells: an emerging target for anticancer immunotherapy
Tongji Hospital · Huazhong University of Science and Technology · +4 more institutions
Abstract
The clinical responses observed following treatment with immune checkpoint inhibitors (ICIs) support immunotherapy as a potential anticancer treatment. However, a large proportion of patients cannot benefit from it due to resistance or relapse, which is most likely attributable to the multiple immunosuppressive cells in the tumor microenvironment (TME). Myeloid-derived suppressor cells (MDSCs), a heterogeneous array of pathologically activated immature cells, are a chief component of immunosuppressive networks. These cells potently suppress T-cell activity and thus contribute to the immune escape of malignant tumors. New findings indicate that targeting MDSCs might be an alternative and promising target for…
Citation impact
- FWCI
- 36.03
- Percentile
- 100%
- References
- 209
Authors
5- YWYuze Wu
Tongji Hospital, Huazhong University of Science and Technology
- MYMing Yi
First Affiliated Hospital Zhejiang University
- MNMengke Niu
Tongji Hospital, Huazhong University of Science and Technology
- QMQi MeiCorresponding
Shanxi Medical University, Shanxi Academy of Medical Sciences, Tongji Hospital, Union Hospital, Huazhong University of Science and Technology
- KWKongming Wu
Tongji Hospital, Huazhong University of Science and Technology
Topics & keywords
- Immunotherapy
- Myeloid-derived Suppressor Cell
- Tumor microenvironment
- Cancer research
- Immune system
- Suppressor
- Cancer immunotherapy
- Biology
- Good health and well-being